Reassessment of the Current American Joint Committee on Cancer Staging System for Pancreatic Neuroendocrine Tumors

2014 ◽  
Vol 218 (2) ◽  
pp. 188-195 ◽  
Author(s):  
Motaz Qadan ◽  
Yifei Ma ◽  
Brendan C. Visser ◽  
Pamela L. Kunz ◽  
George A. Fisher ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Staging System ◽  
Cancer Staging ◽  
Pancreatic Neuroendocrine Tumors ◽  
American Joint Committee

scholarly journals Prognostic Validity of the American Joint Committee on Cancer Eighth Edition Staging System for Well-Differentiated Pancreatic Neuroendocrine Tumors: A Retrospective Multinational Multicenter Study

2020 ◽  
Author(s):  
Hebin Wang ◽  
Ding Ding ◽  
Tingting Qin ◽  
Jun Liu ◽  
Hang Zhang ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Staging System ◽  
Tnm Staging ◽  
Stage I ◽  
Pancreatic Neuroendocrine Tumors ◽  
American Joint Committee ◽  
Staging Systems ◽  
Significant Difference ◽  
Well Differentiated ◽  
Eighth Edition

Abstract Background:There is no widely-accepted staging system for pancreatic neuroendocrine tumors (pNETs). The aim of this study was to validate the American Joint Committee on Cancer (AJCC) 8th edition staging system for well-differentiated (G1/G2) pNETs.Methods:A multicenter dataset (n=1086) was used to evaluate the application of the AJCC 7th and 8th, the European Neuroendocrine Tumor Society (ENETS), and the modified ENETS (mENETS) staging systems for well-differentiated pNETs.Results:The proportion of patients with stage III tumors was extremely low (1.1%) according to the AJCC 7th staging system. For the ENETS staging system, patients with stage IIIA disease had worse estimated mean survival than patients with stage IIIB disease (78.9 vs. 107.3 months). When comparing with patients in stage I, the AJCC 7th, ENETS, and mENETS staging systems showed good performance in discriminating between stages; however, there was no significant difference in some stages when the reference was defined as the earlier stage. When the reference was defined as stage I or the earlier stage, there was a significant inter-stage difference in the AJCC 8th staging system.Conclusions:The AJCC 8th staging system is more suitable for pNETs than other TNM staging systems and may be adopted in clinical practice.

Modified Staging Classification for Pancreatic Neuroendocrine Tumors on the Basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society Systems

2017 ◽  
Vol 35 (3) ◽  
pp. 274-280 ◽  
Author(s):  
Guopei Luo ◽  
Ammar Javed ◽  
Jonathan R. Strosberg ◽  
Kaizhou Jin ◽  
Yu Zhang ◽  
...  
Keyword(s):  
Neuroendocrine Tumor ◽  
Neuroendocrine Tumors ◽  
Statistical Significance ◽  
Staging System ◽  
Hazard Ratio ◽  
Stage Iii ◽  
Pancreatic Neuroendocrine Tumors ◽  
American Joint Committee ◽  
Ajcc Staging ◽  
Staging Classification

Purpose The European Neuroendocrine Tumor Society (ENETS) and the American Joint Committee on Cancer (AJCC) staging classifications are two widely used systems in managing pancreatic neuroendocrine tumors. However, there is no universally accepted system. Methods An analysis was performed to evaluate the application of the ENETS and AJCC staging classifications using the SEER registry (N = 2,529 patients) and a multicentric series (N = 1,143 patients). A modified system was proposed based on analysis of the two existing classifications. The modified system was then validated. Results The proportion of patients with AJCC stage III disease was extremely low for both the SEER series (2.2%) and the multicentric series (2.1%). For the ENETS staging system, patients with stage I disease had a similar prognosis to patients with stage IIA disease, and patients with stage IIIB disease had a lower hazard ratio for death than did patients with stage IIIA disease. We modified the ENETS staging classification by maintaining the ENETS T, N, and M definitions and adopting the AJCC staging definitions. The proportion of patients with stage III disease using the modified ENETS (mENETS) system was higher than that of the AJCC system in both the SEER series (8.9% v 2.2%) and the multicentric series (11.6% v 2.1%). In addition, the hazard ratio of death for patients with stage III disease was higher than that for patients with stage IIB disease. Moreover, statistical significance and proportional distribution were observed in the mENETS staging classification. Conclusion An mENETS staging classification is more suitable for pancreatic neuroendocrine tumors than either the AJCC or ENETS systems and can be adopted in clinical practice.

Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma

2001 ◽  
Vol 19 (16) ◽  
pp. 3635-3648 ◽  
Author(s):  
Charles M. Balch ◽  
Antonio C. Buzaid ◽  
Seng-Jaw Soong ◽  
Michael B. Atkins ◽  
Natale Cascinelli ◽  
...  
Keyword(s):  
Cutaneous Melanoma ◽  
Elevated Serum ◽  
Primary Melanoma ◽  
Staging System ◽  
Distant Metastases ◽  
Lactic Dehydrogenase ◽  
Cancer Staging ◽  
Sixth Edition ◽  
Stage Grouping ◽  
American Joint Committee

PURPOSE: To revise the staging system for cutaneous melanoma under the auspices of the American Joint Committee on Cancer (AJCC). MATERIALS AND METHODS: The prognostic factors analysis described in the companion publication (this issue), as well as evidence from the published literature, was used to assemble the tumor-node-metastasis criteria and stage grouping for the melanoma staging system. RESULTS: Major changes include (1) melanoma thickness and ulceration but not level of invasion to be used in the T category (except for T1 melanomas); (2) the number of metastatic lymph nodes rather than their gross dimensions and the delineation of clinically occult (ie, microscopic) versus clinically apparent (ie, macroscopic) nodal metastases to be used in the N category; (3) the site of distant metastases and the presence of elevated serum lactic dehydrogenase to be used in the M category; (4) an upstaging of all patients with stage I, II, and III disease when a primary melanoma is ulcerated; (5) a merging of satellite metastases around a primary melanoma and in-transit metastases into a single staging entity that is grouped into stage III disease; and (6) a new convention for defining clinical and pathologic staging so as to take into account the staging information gained from intraoperative lymphatic mapping and sentinel node biopsy. CONCLUSION: This revision will become official with publication of the sixth edition of the AJCC Cancer Staging Manual in the year 2002.

Sign in / Sign up

Export Citation Format

Share Document